- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00751153
Raltegravir and Atazanavir Replacing Current Suppressive Treatment Because of Side Effects in Current Treatment
October 8, 2008 updated by: Peter J. Ruane, M.D., Inc.
Open Label Phase 4, 48 Week Pilot Study of the Antiviral Efficacy and Tolerability of the Combination of Isentress™ and ReyatazTM When Substituted for Current Antiviral Regimen in Patients With Viral Suppression But Who Are Experiencing Adverse Events Related to Their Current Antiviral Regimen.
Subjects with HIV who have viral suppression on current regimen but also have side effects/intolerance will change their current regimen to a combination of Raltegravir and Atazanavir and be monitored for viral and immunological response and quality of life.
Study Overview
Detailed Description
Subjects with intolerance to current regimen will receive Raltegravir 400 mg twice daily and Atazanavir 400 mg daily will be monitored for viralogical and immunological outcomes, changes in lipids, renal and hepatic safety and quality of life.
Study Type
Interventional
Enrollment (Anticipated)
40
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Peter J Ruane, MB
- Phone Number: 3239541072
- Email: pjruane@lightsourcemedical.com
Study Contact Backup
- Name: Brian Alas
- Phone Number: 3239541072
- Email: balas@lightsourcemedical.com
Study Locations
-
-
California
-
Los Angeles, California, United States, 90036
- Recruiting
- Medical Practice of Peter Ruane MB
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria
- History of no PI resistance or antiretroviral failure while receiving a PI.
- On a current antiviral regimen with plasma HIV viral load (VL) < 400 copies/ml for 4 months or longer.
- Intolerance to or toxicity with current or alternative regimen(s) with side effects including but not limited to gastrointestinal, neurological, metabolic, or dysmorphic symptoms and/or dyslipidemia.
- Continuously using the same regimen for 3 months prior to Screening.
- Women of childbearing potential must be willing to use effective method(s) of contraception throughout their study participation and for 30 days following the end of the study (see Section 1.10). -Women who are postmenopausal for at least 2 years, women with total hysterectomy and women with tubal ligation are considered of non-childbearing potential.
- Willing to adhere to the prohibitions and restrictions specified in this protocol.
Exclusion Criteria:
- Use of any drug contraindicated in the current US package insert for Atazanavir or in the investigators brochure for Raltegravir, including PPI inhibitors.
- Use of any investigational drug up to 4 weeks prior to screening.
- Prior or current therapy with Raltegravir.
- Allergy to Raltegravir or Atazanavir
- History of medication non-compliance significant to the study regimen as deemed significant by the investigator.
- Known achlorhydria that would inhibit the absorption of Atazanavir
- Concurrent active chronic Hepatitis B requiring therapy with 3TC, FTC or Tenofovir (entecavir permitted).
- AST or ALT >5 times ULN
- Calculated CrCl < 30 ml/min.
- Female subject who is pregnant or breastfeeding.
- General medical condition that may interfere with the assessments and completion of the trial.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Evaluation of the proportion of patients who maintain plasma HIV viral load measurements < 400 copies/ml at week 4, 8, 12, 16, 24, 36 and 48 weeks after switching to Raltegravir and Atazanavir
Time Frame: 48 weeks
|
48 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Evaluation of the proportion of patients who have plasma HIV viral load measurements <50 copies/ml at week 4, 8, 12, 16, 24, 36 and 48 weeks after switching to Raltegravir and Atazanavir
Time Frame: 48 weeks
|
48 weeks
|
Time to virologic failure (defined as 2 consecutive VL measurements > 400 copies/ml on 2 separate clinic visits within 4 weeks)
Time Frame: 48 weeks
|
48 weeks
|
Assessment of CD4 cell count changes at 4, 8, 12, 16, 24, 36 and 48 weeks after switching to Raltegravir and Atazanavir
Time Frame: 48 weeks
|
48 weeks
|
Assessment of lipid changes after change in regimen
Time Frame: 48 weeks
|
48 weeks
|
Determination of incidence, genotypic and phenotypic resistance patterns, in particular to Raltegravir and Atazanavir, in patients in the event of rebound viremia
Time Frame: 48 weeks
|
48 weeks
|
Patient adherence to a regimen of Raltegravir and Atazanavir
Time Frame: 48 weeks
|
48 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Peter J Ruane, MB, Peter J Ruane Md Inc
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2008
Primary Completion (ANTICIPATED)
October 1, 2009
Study Completion (ANTICIPATED)
December 1, 2009
Study Registration Dates
First Submitted
September 10, 2008
First Submitted That Met QC Criteria
September 10, 2008
First Posted (ESTIMATE)
September 11, 2008
Study Record Updates
Last Update Posted (ESTIMATE)
October 9, 2008
Last Update Submitted That Met QC Criteria
October 8, 2008
Last Verified
September 1, 2008
More Information
Terms related to this study
Additional Relevant MeSH Terms
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Sexually Transmitted Diseases, Viral
- Sexually Transmitted Diseases
- Lentivirus Infections
- Retroviridae Infections
- Immunologic Deficiency Syndromes
- Immune System Diseases
- HIV Infections
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Enzyme Inhibitors
- Anti-HIV Agents
- Anti-Retroviral Agents
- Protease Inhibitors
- HIV Integrase Inhibitors
- Integrase Inhibitors
- HIV Protease Inhibitors
- Viral Protease Inhibitors
- Raltegravir Potassium
- Atazanavir Sulfate
Other Study ID Numbers
- Merck IISP #33040
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV Infections
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
University of California, San DiegoUniversity of California, Los Angeles; University of Southern California; California... and other collaboratorsCompleted
-
Gérond'ifRecruiting
-
University of California, DavisCompleted
-
University of California, San DiegoNational Center for Complementary and Integrative Health (NCCIH)CompletedHIV PositiveUnited States
-
University of ChicagoUniversity of Athens; National Development and Research Institutes, Inc.Completed
-
HIV Prevention Trials NetworkNational Institute on Drug Abuse (NIDA); National Institute of Allergy and...CompletedHIV PositiveIndonesia, Ukraine, Vietnam
-
University of ZimbabweCompleted
-
Florida International UniversityCompleted
-
Boston Children's HospitalNational Institute on Minority Health and Health Disparities (NIMHD)Completed
Clinical Trials on Raltegravir and Atazanavir
-
Bristol-Myers SquibbMerck Sharp & Dohme LLCCompleted
-
Giovanni Di PerriUniversity of Turin, Italy; University of MilanTerminatedHIV Infection | OsteopeniaItaly
-
Yale UniversityBristol-Myers Squibb; Merck Sharp & Dohme LLCCompletedHIV Infections | Human Immunodeficiency Virus | AIDS | Acquired Immune Deficiency SyndromeUnited States
-
Kirby InstituteCompleted
-
Community Research Initiative of New EnglandBristol-Myers Squibb; Merck Sharp & Dohme LLCCompleted
-
Radboud University Medical CenterCompletedHIV Infections | HIV InfectionGermany, Netherlands
-
St. James's Hospital, IrelandUnknownHIV Infections | Hepatitis CIreland
-
University Hospital, BonnDr. Axel Baumgarten, Berlin; Dr. Christoph Stephan, Frankfurt/M; Dr. Stefan Esser... and other collaboratorsWithdrawn
-
Pedro CahnMerck Sharp & Dohme LLCUnknownChronic Infection With HIVArgentina
-
The University of Texas Health Science Center,...Merck Sharp & Dohme LLCCompleted